Evaluation of the Venous Excess Ultrasound Score (VExUS) After Circulating Volume Modification in Children.
Launched by UNIVERSITY HOSPITAL, TOULOUSE · Nov 15, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool called the Venous Excess Ultrasound Score (VExUS) to see how well it can help doctors understand the effects of blood volume changes in children. The trial aims to find out if this score, which was originally tested on adults, can also be useful for children in intensive care. The study will look at how venous overload, or too much blood in the veins, affects organ function and overall health in young patients.
To be eligible for the trial, children aged between 1 and 18 years who are receiving certain medical treatments that involve blood volume changes can participate. However, children whose parents do not agree, those with specific medical conditions, or those who cannot tolerate the ultrasound examination will not be included. Participants in the trial will have a simple ultrasound test to measure their VExUS score, which can help doctors provide better care for them. It’s important for families to know that this study is focused on improving our understanding of how to manage blood volume in critically ill children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged between 1 and 18 years, receiving extrarenal purification with UF \> 10 ml/kg, bleeding \> 10 ml/kg or vascular filling \> 10 ml/kg
- Exclusion Criteria:
- • Refusal of the patient or opposition of one or both holders of parental authority.
- • Minors with parental authority.
- • Ultrafiltration time \> 6h.
- • Curarized patient, known abnormality of the hepatorenal venous network.
- • Patient agitated or poor tolerance of the examination.
- • Parents under court protection, guardianship or curatorship.
About University Hospital, Toulouse
The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Patients applied
Trial Officials
Montserrat SIERRA COLOMINA, MD
Principal Investigator
CHU Toulouse
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported